Recent Quotes (30 days)

You have no recent quotes
chg | %

Shire PLC  

(Public, LON:SHP)   Watch this stock  
Find more results forSHP
3,679.59
-64.41 (-1.72%)
Nov 17 - Close
LON real-time data - Disclaimer
Currency in GBX unless noted
Range 3,650.00 - 3,713.00
52 week 3,435.50 - 5,067.00
Open 3,667.00
Vol / Avg. 5.22M/2.79M
Mkt cap 33,388.28M*
P/E 27.45
Div/yield 3.85*
EPS 1.34*
Shares 908.64M
Beta     -
Inst. own     -
*GBP
Oct 27, 2017
Q3 2017 Shire PLC Earnings Call
Oct 27, 2017
Q3 2017 Shire PLC Earnings Release
Sep 14, 2017
Shire PLC at Bank of America Merrill Lynch Health Care Conference - Webcast
Sep 12, 2017
Shire PLC at Morgan Stanley Healthcare Conference - Webcast
  

Key stats and ratios

Q3 (Sep '17) 2016
Net profit margin 15.00% 5.37%
Operating margin 19.16% 8.45%
EBITD margin - 30.21%
Return on average assets 3.30% 1.46%
Return on average equity 6.92% 3.11%
Employees 23,906 -
CDP Score - B

Address

Miesian Plaza 50-58 Baggot Street Lower, Block 2
DUBLIN, D02 HW68
Ireland
+353-1-6096000 (Phone)
+44-1256-894708 (Fax)

Website links

External links

Analyst Estimates - BusinessWeek
Options - MarketWatch
Director Dealings - Yahoo Finance

Description

Shire plc is a biotech company focused on serving people with rare diseases and other specialized conditions. The Company's segment is engaged in research, development, licensing, manufacturing, marketing, distribution and sale of specialist medicines. It focuses its development resources on projects in various therapeutic areas (TAs), including Neuroscience, Ophthalmology, Hematology, Oncology, Immunology, Gastrointestinal (GI)/Metabolic/Endocrinology Diseases. Its Hematology products include ADVATE (Antihemophilic Factor (Recombinant)), ADYNOVATE/ADYNOVI (Antihemophilic Factor (Recombinant), PEGylated)), RIXUBIS (Coagulation Factor IX (Recombinant)), VONVENDI (von Willebrand factor (Recombinant)) and FEIBA (Anti-Inhibitor Coagulant Complex). Its Genetic Diseases products include CINRYZE (C1 esterase inhibitor (human)), FIRAZYR (icatibant), ELAPRASE (idursulfase), REPLAGAL (agalsidase alfa) and VPRIV (velaglucerase alfa).

Officers and directors

Flemming Ornskov M.D. Chief Executive Officer, Executive Director
Age: 59
Jeffrey Poulton Chief Financial Officer, Executive Director
Age: 49
Joanne Cordeiro Chief Human Resource Officer
Gisele Dion Chief Accounting Officer, Corporate Controller
Age: 51
William Mordan General Counsel, Company Secretary
Age: 47
Perry Sternberg Head - U.S. Commercial
Age: 48
Kim Stratton Head - International Commercial
Age: 54
Philip J. Vickers Head - Research and Development
Age: 56
Matthew Walker Head - Technical Operations
Age: 53
Susan Saltzbart Kilsby Independent Non-Executive Chairman of the Board
Age: 58